<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04181203</url>
  </required_header>
  <id_info>
    <org_study_id>GETUG-AFU33 UC-0160/1702</org_study_id>
    <secondary_id>2017-000155-21</secondary_id>
    <nct_id>NCT04181203</nct_id>
  </id_info>
  <brief_title>Combined Apalutamide, Radiotherapy, and LHRH Agonist in Prostate Cancer Patients After Prostatectomy</brief_title>
  <acronym>CARLHA-2</acronym>
  <official_title>An Open Label, Randomized, Phase III Study, Evaluating the Efficacy of a Combination of Apalutamide With Radiotherapy and LHRH Agonist in High-risk Postprostatectomy Biochemically Relapsed Prostate Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UNICANCER</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen Pharmaceutica</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>UNICANCER</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, randomized, open label, phase III study comparing the efficacy and&#xD;
      safety of apatulamide combined with concomitant prostate-bed salvage radiotherapy (SRT) and&#xD;
      androgen deprivation therapy (ADT) versus concomitant prostate-bed SRT and ADT in high-risk&#xD;
      postprostatectomy biochemically relapsed prostate cancer patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of the CARLHA-2 study is to determine if the combination of apalutamide with 6&#xD;
      months of LHRH agonists and radiotherapy results in an improvement of progression-free&#xD;
      survival (PFS) in comparison to the combination of 6 months of LHRH agonists with&#xD;
      radiotherapy in high-risk postprostatectomy biochemically relapsed prostate cancer patients.&#xD;
&#xD;
      Radical prostatectomy must have been done at least 6 months before inclusion and is not part&#xD;
      of this study.&#xD;
&#xD;
      Patients after radical prostatectomy and biochemical relapse will be randomized in a 1:1&#xD;
      ratio to receive either 6 months of LHRH agonists + SRT or 6 months of LHRH agonists + SRT +&#xD;
      6 months of apalutamide.&#xD;
&#xD;
      The stratification variables include Gleason score, prostate-specific antigen (PSA), negative&#xD;
      resection margins, extension to seminal vesicle(s), and PSA doubling time.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 9, 2020</start_date>
  <completion_date type="Anticipated">December 28, 2033</completion_date>
  <primary_completion_date type="Anticipated">September 28, 2028</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>5 years</time_frame>
    <description>PFS is defined as the time from the date of randomization to the date of first evidence of loco-regional recurrences, or distant metastases, or death from any cause whichever occurs first, or the date of last known follow-up alive without any such events.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cancer-specific overall survival</measure>
    <time_frame>10 years</time_frame>
    <description>Cancer-specific overall survival is defined as the time from the date of randomization to the date of death related to prostate cancer or the date of last known follow-up alive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>10 years</time_frame>
    <description>OS is defined as the time from the date of randomization to the date of death from any cause or the date of last known follow-up alive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical relapse-free survival</measure>
    <time_frame>10 years</time_frame>
    <description>Biochemical relapse-free survival will be retrospectively defined by the interval between the date of randomization and the date of the first PSA elevation following the 6-months treatment in both arms (PSA â‰¥0.5 ng/mL confirmed by two consecutive PSA increases over a 2-month interval).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to castration resistance</measure>
    <time_frame>10 years</time_frame>
    <description>The time to castration resistance is defined as the time from the date of randomization to the date of appearance of castration resistance defined in the European Association of Urology (EAU) guidelines.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events graded according to the NCI Common Terminology Criteria for Adverse Events version 5.0</measure>
    <time_frame>Throughout study completion, up to 10 years</time_frame>
    <description>The NCI Common Terminology Criteria for Adverse Events is a descriptive terminology which can be utilized for Adverse Event (AE) reporting. A grading (severity) scale is provided for each AE term.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life questionnaire - Core 30 (QLQ-C30)</measure>
    <time_frame>At baseline, 3 months, 6 months, every 6 months up to 5 years then every 12 months up to 10 years</time_frame>
    <description>Developed by the EORTC, this self-reported questionnaire assesses the health-related quality of life of cancer patients in clinical trials.&#xD;
The questionnaire includes five functional scales (physical, everyday activity, cognitive, emotional, and social), three symptom scales (fatigue, pain, nausea and vomiting), a health/quality of life overall scale, and a number of additional elements assessing common symptoms (including dyspnea, loss of appetite, insomnia, constipation, and diarrhea), as well as, the perceived financial impact of the disease.&#xD;
All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Questionnaire - Prostate Cancer Module (QLQ-PR25)</measure>
    <time_frame>At baseline, 3 months, 6 months, every 6 months up to 5 years then every 12 months up to 10 years</time_frame>
    <description>This EORTC prostate cancer specific questionnaire is intended to supplement the QLQ-C30.&#xD;
The prostate cancer module is a 25-item questionnaire designed for use among patients with localized and metastatic prostate cancer. It includes subscales assessing urinary symptoms (9 items), bowel symptoms (4 items), treatment-related symptoms (6 items) and sexual functioning (6 items). Using a 4-point Likert scale (1 = &quot;not at all&quot;, 2 = &quot;a little&quot;, 3 = &quot;quite a bit&quot;, and 4 = &quot;very much&quot;), patients indicate the degree to which they have experienced symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>International Index of Erectile Function (IIEF-5)</measure>
    <time_frame>At baseline, 3 months, 6 months, every 6 months up to 5 years then every 12 months up to 10 years</time_frame>
    <description>International Index of Erectile Function (IIEF-5) is multidimensional, self-administered questionnaire composed of 15 questions that examine the 4 main domains of male sexual function (erectile function [6 items], orgasmic function [2 items], sexual desire [2 items], and intercourse satisfaction [3 items]) and overall satisfaction (2 items). Using a 6-point Likert scale (questions 1 to 10) and 5-point Likert scale (questions 15 to 15), patients indicate the degree to which they have experienced symptoms. The total score for each domain can therefore classifies the severity of erectile dysfunction into five categories: no (score 26-30), mild (22-25), mild to moderate (17-21), moderate (11-16), and severe (1-10) erectile dysfunction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lawton Instrumental Activities of Daily Living (IADL) Scale</measure>
    <time_frame>At baseline, 3 months, 6 months, every 6 months up to 5 years then every 12 months up to 10 years</time_frame>
    <description>Lawton Instrumental Activities of Daily Living (IADL) Scale is a self-reported questionnaire to assess independent living skills for older adults. This questionnaire, composed of 31 questions organized into 8 domains (ability to use telephone, shopping, food preparation, housekeeping, laundering, mode of transportation, responsibility for own medications, and ability to handle finances), is designed to identify improvement or deterioration of a person functioning over time. Each domain is scored 0-1 for a summary score ranging from 0 (low function, dependent) to 8 (high function, independent).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">490</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>SRT + 6 months of LHRHa</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment with LHRHa will start 4 weeks before the first RT fraction (i.e Day 1 of Week 1 of treatment period.) The total duration of the LHRHa treatment is 6 months.&#xD;
SRT will start 4 weeks after the first administration of LHRHa (i.e Day 1 of Week 5 of treatment period.). The total duration of SRT is 6.5 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SRT + 6 months of LHRHa + 6 months of Apalutamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with LHRHa will start 4 weeks before the first RT fraction (i.e Day 1 of Week 1 of treatment period.) The total duration of the LHRHa treatment is 6 months.&#xD;
Treatment with apalutamide (240 mg PO daily) should start the same day as the first LHRHa administration, for 6 months.&#xD;
SRT will start 4 weeks after the first administration of LHRHa (i.e Day 1 of Week 5 of treatment period.). The total duration of SRT is 6.5 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apalutamide</intervention_name>
    <description>240 mg PO daily should start the same day as the first LHRHa administration for 6 months.&#xD;
months.</description>
    <arm_group_label>SRT + 6 months of LHRHa + 6 months of Apalutamide</arm_group_label>
    <other_name>ARN-509</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Salvage radiotherapy (SRT)</intervention_name>
    <description>The SRT treatment will be administered to a total dose of 66 Gy (in 33 fractions of 2 Gy) directed at the prostate bed with an additional 56.1 Gy (in 33 fractions of 1.7 Gy) directed at the pelvis region. The pelvis will be irradiated in all patients.&#xD;
An additional simultaneously integrated boost of 69.3 Gy (in 33 fractions of 2.1 Gy) can be delivered to a local relapse based on Positron Emission Tomography - Computed Tomography (PET/CT) and Magnetic Resonance Imaging (MRI) images.</description>
    <arm_group_label>SRT + 6 months of LHRHa</arm_group_label>
    <arm_group_label>SRT + 6 months of LHRHa + 6 months of Apalutamide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Luteinising Hormone Releasing Hormone agonist (LHRHa)</intervention_name>
    <description>Doses of LHRHa may vary due to availability of different brand names and pharmaceutical forms. It will be left to the discretion of the investigator.</description>
    <arm_group_label>SRT + 6 months of LHRHa</arm_group_label>
    <arm_group_label>SRT + 6 months of LHRHa + 6 months of Apalutamide</arm_group_label>
    <other_name>leuprolide, goserelin, triptorelin acetate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients must have signed a written informed consent form prior to any trial specific&#xD;
             procedures&#xD;
&#xD;
          2. Age â‰¥18 years old and â‰¤80 years old&#xD;
&#xD;
          3. Histologically confirmed diagnosis of prostate adenocarcinoma treated primarily with&#xD;
             radical prostatectomy&#xD;
&#xD;
          4. Pathologically proven to be lymph node negative by pelvic lymphadenectomy (N0) or&#xD;
             lymph node status pathologically unknown (undissected pelvic lymph nodes [Nx])&#xD;
&#xD;
          5. Tumor stage pT2, pT3 or pT4* (*only in case of bladder neck involvement)&#xD;
&#xD;
          6. Patients should have no clinical and radiological signs (18FCH-PET CT-scan or&#xD;
             68Ga-PSMA-PET CT-scan) of metastatic disease. Patients with a local relapse detected&#xD;
             on PET CT-scan can be randomized&#xD;
&#xD;
          7. Eastern Cooperative Oncology Group (ECOG) performance status â‰¤1&#xD;
&#xD;
          8. PSA â‰¤0.5 ng/mL after radical prostatectomy (dosage performed within 3 months after&#xD;
             surgery)&#xD;
&#xD;
          9. PSA â‰¥0.2 ng/mL and â‰¤2 ng/mL at the time of randomization with an elevation of PSA over&#xD;
             three consecutive assays&#xD;
&#xD;
         10. At least 3 months between radical prostatectomy and inclusion&#xD;
&#xD;
         11. High-risk features as defined by at least one of these characteristics: PSA at relapse&#xD;
             &gt;0.5 ng/mL or Gleason score &gt;7 or tumor stage pT3b or resection margins R0 or PSA&#xD;
             doubling time â‰¤6 months&#xD;
&#xD;
         12. Adequate renal function: serum creatinine &lt;1.5 x upper limit of normal (ULN) or a&#xD;
             calculated corrected creatinine clearance â‰¥60 mL/min according to the Cockcroft-Gault&#xD;
             formula, creatinemia &lt;2 ULN&#xD;
&#xD;
         13. Adequate hepatic function: total bilirubin â‰¤1.5 x ULN (unless documented Gilbert's&#xD;
             syndrome), aspartate aminotransferase (AST) and alanine aminotransferase (ALT) â‰¤2.5 x&#xD;
             ULN&#xD;
&#xD;
         14. Patients with QTc prolongation &lt;500 ms, inclusion should considered after close&#xD;
             benefit/risk assessment and cardiologist advice&#xD;
&#xD;
         15. Patients with female partners of reproductive potential should agree to use effective&#xD;
             contraceptive method during treatment period and for 3 months after the last dose of&#xD;
             apalutamide or for 6 months after the last fraction of radiotherapy&#xD;
&#xD;
         16. Patients must be willing and able to comply with the protocol for the duration of the&#xD;
             study including undergoing treatment and scheduled visits and examinations&#xD;
&#xD;
         17. Patients must be affiliated to the Social Security System&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Histologically proven lymph nodes involvement at initial lymphadenectomy: pN1, pN2,&#xD;
             pN3&#xD;
&#xD;
          2. Previous treatment with hormone therapy for prostate cancer&#xD;
&#xD;
          3. Histology other than adenocarcinoma&#xD;
&#xD;
          4. Surgical or chemical castration&#xD;
&#xD;
          5. Other malignancy except adequately treated basal cell carcinoma of the skin or other&#xD;
             malignancy from which the patient has been cured for at least 5 years&#xD;
&#xD;
          6. Previous pelvic radiotherapy&#xD;
&#xD;
          7. History of Inflammatory bowel disease or any malabsorption syndrome or conditions that&#xD;
             would interfere with enteral absorption&#xD;
&#xD;
          8. Uncontrolled hypertension (defined as systolic blood pressure (BP) â‰¥140 mmHg or&#xD;
             diastolic BP â‰¥90 mmHg). Patients with a history of hypertension are allowed provided&#xD;
             blood pressure is controlled by anti-hypertensive treatment&#xD;
&#xD;
          9. Clinically significant history of liver disease consistent with Child-Pugh class B or&#xD;
             C&#xD;
&#xD;
         10. History of seizure or condition that may pre-dispose to seizure (including, but not&#xD;
             limited to prior stroke, transient ischemic attack or loss of consciousness â‰¤1 year&#xD;
             prior to randomization; brain arteriovenous malformation or intracranial masses such&#xD;
             as schwannomas and meningiomas that are causing edema or mass effect)&#xD;
&#xD;
         11. Medications known to lower the seizure threshold must be discontinued or substituted&#xD;
             at least 4 weeks prior to study entry&#xD;
&#xD;
         12. Severe or unstable angina, myocardial infarction, symptomatic congestive heart&#xD;
             failure, arterial or venous thromboembolic events (e.g pulmonary embolism,&#xD;
             cerebrovascular accident including transient ischemic attacks) or clinically&#xD;
             significant ventricular arrhythmias within 6 months prior to randomization&#xD;
&#xD;
         13. Certain risk factors for abnormal heart rhythms/QT prolongation: torsade de pointes&#xD;
             ventricular arrhythmias (e.g, heart failure, hypokalemia, or a family history of a&#xD;
             long QT syndrome), a QT or corrected QT (QTc) interval &gt;500 ms at baseline&#xD;
&#xD;
         14. Medications known to prolong QTc&#xD;
&#xD;
         15. Known hypersensitivity to apalutamide or to any of its components&#xD;
&#xD;
         16. Galactosemia, Glucose-galactose malabsorption or lactase deficiency&#xD;
&#xD;
         17. Inability or willingness to swallow oral medication&#xD;
&#xD;
         18. Individual deprived of liberty or placed under the authority of a tutor&#xD;
&#xD;
         19. Patients already included in another therapeutic trial with an experimental drug or&#xD;
             having been given an experimental drug within the 30 days before inclusion&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>StÃ©phane SUPIOT</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut de CancÃ©rologie de l'Ouest - Saint Herblain</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>UNICANCER</last_name>
    <phone>+33 (0) 1 44 23 04 04</phone>
    <email>getug-afu33@unicancer.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Florence TANTOT</last_name>
    <phone>+33 (0)1 73 77 55 43</phone>
    <email>f-tantot@unicancer.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Clinique Claude Bernard</name>
      <address>
        <city>Albi</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pierre AUBERDIAC</last_name>
      <email>auberdiac@claude-bernard-albi.com</email>
    </contact>
    <investigator>
      <last_name>Pierre AUBERDIAC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de CancÃ©rologie de l'Ouest</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>StÃ©phane SUPIOT</last_name>
      <email>stephane.supiot@ico.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>StÃ©phane SUPIOT</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut BergoniÃ©</name>
      <address>
        <city>Bordeau</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Paul SARGOS</last_name>
      <email>p.sargos@bordeaux.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Paul SARGOS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Georges FranÃ§ois LECLERC</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Magali QUIVRIN</last_name>
      <email>mquivrin@cgfl.fr</email>
    </contact>
    <investigator>
      <last_name>Magali QUIVRIN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Emile ROUX</name>
      <address>
        <city>Le Puy-en-Velay</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>KiÃªÃ¹ LÃŠ</last_name>
      <email>kieugiang.le@laposte.net</email>
    </contact>
    <investigator>
      <last_name>KiÃªÃ¹ LÃŠ</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David PASQUIER</last_name>
      <email>d-pasquier@o-lambret.fr</email>
    </contact>
    <investigator>
      <last_name>David PASQUIER</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de CancÃ©rologie de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>David AZRIA</last_name>
      <email>david.azria@icm.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>David AZRIA</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shakeel SUMODHEE</last_name>
      <email>shakeel.sumodhee@nice.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Shakeel SUMODHEE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Jean Godinot</name>
      <address>
        <city>Reims</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>GrÃ©goire BOUCHE</last_name>
      <email>gregoire.bouche@reims.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>GrÃ©goire BOUCHE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ahmed BENYOUCEF</last_name>
      <email>ahmed.benyoucef@chb.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Ahmed BENYOUCEF</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de CancÃ©rologie de l'Ouest</name>
      <address>
        <city>Saint Herblain</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>StÃ©phane SUPIOT</last_name>
      <email>stephane.supiot@ico.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>StÃ©phane SUPIOT</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de CancÃ©rologie de la Loire Lucien Neuwirth</name>
      <address>
        <city>Saint-Priest-en-Jarez</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas MAGNE</last_name>
      <email>nicolas.magne@icloire.fr</email>
    </contact>
    <investigator>
      <last_name>Nicolas MAGNE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de CancÃ©rologie Paris Nord</name>
      <address>
        <city>Sarcelles</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Guillaume SERGENT</last_name>
      <email>g.sergent@icpn.care</email>
    </contact>
    <investigator>
      <last_name>Guillaume SERGENT</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Paul STRAUSS</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>InÃ¨s MENOUX</last_name>
      <email>ines.srour@gmail.com</email>
    </contact>
    <investigator>
      <last_name>InÃ¨s MENOUX</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique Pasteur - ONCORAD</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Igor LATORZEFF</last_name>
      <email>ilatorzeff@clinique-pasteur.com</email>
    </contact>
    <investigator>
      <last_name>Igor LATORZEFF</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>November 26, 2019</study_first_submitted>
  <study_first_submitted_qc>November 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 29, 2019</study_first_posted>
  <last_update_submitted>September 22, 2021</last_update_submitted>
  <last_update_submitted_qc>September 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Apalutamide</keyword>
  <keyword>Salvage radiotherapy</keyword>
  <keyword>Radical prostatectomy</keyword>
  <keyword>PSA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leuprolide</mesh_term>
    <mesh_term>Goserelin</mesh_term>
    <mesh_term>Triptorelin Pamoate</mesh_term>
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

